OLO ALERT: Bragar Eagel & Squire, P.C. is Investigating Olo, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
- 63
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Olo, Inc. (NYSE: OLO) on behalf of long-term stockholders following a class action complaint that was filed against Olo on September 26, 2022 with a Class Period from August 11, 2021 and August 11, 2022. Our investigation concerns whether the board of directors of Olo have breached their fiduciary duties to the company.
The complaint alleges that defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the Company's business, operations, and prospects, which were known to defendants or recklessly disregarded by them. Specifically, defendants misrepresented and/or failed to disclose that: (i) Subway was ending its contract with the Company; (ii) the Company's key business metric - active locations - could not continue to grow as defendants touted due to the loss of Subway's business; and (iii) as a result, defendants' statements about the Company's business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
If you are a long-term stockholder of Olo, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230125005260/en/
- Pharnext a présenté les données de l'étude pivot de Phase III de PXT3003 dans la maladie de Charcot-Marie-Tooth de type 1A au congrès annuel de CMT-France
- Hermès International : Chiffre d'affaires du 1er trimestre 2024
- GALISMMO SCA Entité française du groupe Galimmo Real Estate - Information financière au 31 mars 2024
- RESULTATS ANNUELS 2023
- BOOSTHEAT ANNONCE UNE PERCÉE MAJEURE POUR UNE NOUVELLE GÉNÉRATION DE POMPES À CHALEUR AVEC LA VALIDATION TECHNIQUE DU PREMIER COMPRESSEUR HYBRIDE TOUT-EN-UN
- Quantum Genomics annonce avoir obtenu l'approbation de l'Assemblée Générale des Actionnaires sur la réduction de son capital social et sur l'apport en nature de 100% des titres d'ExactCure.